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Administration of HAART has resulted in significant
improvements in the survival of HIV-infected patients.
H o w e v e r ,d e s p i t en o wr e a c h i n gap o i n tw h e r ew ec a n
achieve durable, maximal suppression of plasma viral
load in most of our HAART-treated patients, non-
AIDS-related morbidity and mortality among these
patients remain a concern. Conditions typical of aging,
such as cardiovascular disease and cancer, are seen at a
higher rate in HIV-infected patients compared to the
general population, potentially because the ability of
HAART to restore immunocompetence appears incom-
plete–even in patients who have long-term undetectable
HIV-1 RNA.
New insights into the pathogenesis of HIV-1 infection
highlight several new and promising areas of investiga-
tion for immune-based therapies, including strategies
that target T-cell homeostasis and immune activation,
as well those targeted at restoring immune responses
directed against HIV.
The rationale behind the investigation of a of cyto-
kines such as IL-2 and IL-7 as adjunctive therapies to
antiretroviral treatment is to improve the restoration of
the immune system and improve HIV-directed immune
responses. Among cytokines, IL-2, was extensively stu-
died in several phase II and two large phase III studies.
Results from these studies showed that IL-2 increases
signficantly CD4 counts in the long term. However, this
biological effect did not translate into clinical benefit.
These results raise several questions about the function-
ality of IL-2 expanded CD4 T cells that will be
discussed.
The potential interest of IL-7 is based on its crucial
role on T cell homeostasis both in thymic output and
peripheral T proliferation and survival. This new pro-
mising cytokine is currently under evaluation is several
I/II clinical trials in chronically HIV-infected patients
with low level of immune restoration despite controlled
viral load. Results from these studies will be presented
and discussed.
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